GEN Exclusives

More »

GEN News Highlights

More »
Jun 18, 2012

Debiopharm Nabs Rights to Ascepion’s Preclinical Multikinase Inhibitor

  • Debiopharm negotiated an exclusive, worldwide development and commercialization license to China-based Ascepion Pharmaceuticals’ preclinical-stage multikinase inhibitor ASP-08126 (Debio 1144). The drug is an orally available small molecule that is designed to inhibit several tyrosine kinase oncogenes implicated in cancer growth, metastasis, and angiogenesis. Debiopharm says the compound has potential utility in the treatment of solid tumors both as monotherapy or in comination with other anticancer drugs.

    Ascepion is leveraging an integrated technology platform spanning molecular structure-based drug design, chemical synthesis, drug screening biology, and preclinical research for the discovery of small molecule anticancer drugs that target signal transduction pathways. Additional preclinical candidates include ASP-502D, an oral receptor tyrosine kinase inhibitor that blocks tumor angiogenesis and blood supply, and ASP-08112, an orally available, differentiated small molecule multityrosine kinase inhibitor

    Ascepion has in addition established a chemical service platform to provide APIs, biologically active reference compounds, and pharmaceutical intermediates. Services include custom API synthesis, chemical process development, and technology transfer. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?